Navigation Links
Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients
Date:10/18/2011

SAN MATEO, Calif., Oct. 18, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed patient dosing of an open-label Phase I clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. The trial was conducted pursuant to Nile's previously announced collaboration with Medtronic and was an important step towards developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period. This program was granted Fast Track status by the United States Food and Drug Administration.

The Phase I clinical trial was a placebo-controlled study evaluating PK and PD of cenderitide when administered to chronic heart failure patients as a subcutaneous bolus injection or as a subcutaneous infusion. The trial was designed to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous infusion of either of two fixed doses of cenderitide or placebo, delivered through Medtronic's subcutaneous pump technology.

In September, Nile added a Part C to the trial, with an objective to confirm an observed relationship between a patient's weight and cenderitide's pharmacokinetics. In Part C, 12 patients received a 24-hour continuous infusion of either a weight-based dose of cenderitide, or placebo, delivered through Medtronic's subcutaneous pump technology.

"We achieved our objectives for this trial, which was to determine dosing levels for t
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Indiana blocked the sale of more ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Calif., Oct. 28 Watson Pharmaceuticals, Inc. (NYSE: ... announced today that its subsidiary Watson Laboratories, Inc. ... on outstanding patent litigation related to Watson,s Oxytrol® ... August 19, 2008, Barr submitted an Abbreviated New ...
... 27 Cambrex Corporation (NYSE: CBM ) announced that third quarter 2009 financial results will be ... conference call to discuss the third quarter 2009 financial results. , , ... 2009 Earnings Conference Call, When: ... 1-888-634-4003 for U.S., ...
Cached Medicine Technology:Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:8/21/2014)... DURHAM, NC -- Researchers have pinpointed the environmental source ... in Southern California for decades. It literally grows on ... project of a 13-year-old girl, who spent the summer ... Angeles hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... (HealthDay News) -- Not only is eating better and exercising ... of health-care dollars a year, a new study finds. ... health sciences at Wake Forest Baptist Medical Center in Winston-Salem, ... 2 diabetes patients. Participants ranged in age ... an intensive "lifestyle change program" focused on diet and exercise, ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2
... is associated with a statistically significant increase in cancer risk ... of the breast, liver, rectum, and upper aero-digestive tract combined, ... of the Journal of the National Cancer Institute. ... known about the impact of low to moderate alcohol consumption ...
... are sent to a cardiologist to go through a standard ... evidence of coronary artery disease which is the most common ... in men, and these women are sent home with little ... complaining of similar symptoms and are more likely to develop ...
... Postpartum depression is a seriousand often undiagnosedcondition affecting about ... the causes might include personal history of depression, stressful ... support. Left untreated, it can have lasting negative effects ... development. , In the first study of ...
... And that can pose a big public health threat, ... Following their release from Texas prisons, only 5 percent ... to treat their condition within the necessary 10 days, ... [antiretroviral therapy] at this time are at increased risk ...
... Experts agree that field needs more rigorous trials to aid ... of the guidelines for cardiac care issued by the American ... supported by the kind of gold-standard evidence that doctors respect ... come from heretics crying in the wilderness. One author of ...
... Telekenex, Inc ("Telekenex"), today announced it has ... MPLS network over the weekend from Straitshot Communications ... the challenge and worked straight through the weekend ... its network. One of these companies, Evergreen ...
Cached Medicine News:Health News:Million women study shows even moderate alcohol consumption associated with increased cancer risk 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Diabetes a risk factor for postpartum depression 2Health News:Most HIV-Infected Prisoners Go Untreated After Release 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 3Health News:Evergreen Healthcare and Others Successfully Migrate to the Telekenex Network From Straitshot 2
Single-Piece PMMA Intraocular Lenses....
Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
STABIBAG Hydrophilic Acrylic Lens....
Medicine Products: